The panorama of acceptance of the CoronaVac vaccine is slowly changing. Until the beginning of November the product was not accepted for Brazilians in Canada. The good news, however, is that if you are one of those who intend to travel there, just wait for the month to end: the Canadian government has already announced that, as of November 30, it will accept Brazilians vaccinated with the vaccine.
The government thus opens space for the most used product around here, in addition to accepting two other brands, Sinopharm and Covaxin. The country has accepted since September vaccinated with Pfizer-Biotech, Moderna, Janssen and AstraZeneca, and joins others, such as the United States, which also announced the inclusion of the product in the list of approved.
Canada opens its borders
THE Canada opens its borders for foreign tourists, including Brazil, from September 2021. Since the coronavirus began to spread in March 2020, the country has been strictly controlling the movement of people.
Health authorities released the news on social media along with a list of requirements, including: not having symptoms or signs of COVID-19; having been vaccinated with one of the vaccines initially selected (AstraZeneca and Covishield, originally from India), Janssen, Moderna and Pfizer; the last dose of vaccine must have been administered at least 14 days ago; the digital vaccination certificate must be issued by the ArriveCAN platform; if you have never been infected with the coronavirus, a PCR test performed within 72 hours of arrival should be negative.
The reopening also made the Air Canada resume flights between the two countries. It is estimated that, until the beginning of December, the number of flights will gradually increase. According to data provided by the Canadian government, as of August 28, 76,35% of the population aged 12 and over had been fully vaccinated, while 83,42% had at least one dose of the antiviral vaccine.
According to a text published on the Butantã Institute website, CoronaVac is the most used vaccine in the world against Covid-19. According to the source, “(the vaccine) represents 24% of the total production of immunizations against Covid-19, with 1.8 billion doses. According to the entity, which represents the pharmaceutical industry at the World Health Organization (WHO), one in four doses of vaccine is CoronaVac, which places the immunizer as the most used on the entire planet in the fight against the pandemic”.
According to the manufacturer's report, in September the world production of vaccines against Covid-19 should exceed the mark of 7.5 billion doses. Five vaccines account for 95% of the volume: in addition to CoronaVac (1.8 billion doses, or 24%), vaccines from Chinese drugmaker Sinopharm and Pfizer (tied for second with 1.65 billion doses or 22% of the total each) , the AstraZeneca/Oxford vaccine (1.2 billion doses, or 16% of the total) and Moderna (450 million doses, or 6% of the total).
It is worth remembering that both CoronaVac and Sinopharm’s immunizer are produced using inactivated virus technology, that is, “classical inactivated virus vaccines, whose technology has been known for decades, account for almost half of world production (46%, or 3.45 billion doses) ”, concludes the official Butantã website.
A study published in the scientific journal The Lancet Infectious Diseases showed that CoronaVac produced only between 29 and 33% of the adverse reactions, and all were very mild. This is a good indicator that proves the high safety of immunizers and also points to a lower incidence of adverse reactions among all vaccines approved by the World Health Organization for emergency use.
The study was conducted by researchers from the Centers for Disease Control and Prevention in Hangzhou, Nanjing and Jiangsu, scientists from the Chinese Academy of Sciences and researchers from Kexing. A total of 744 volunteers participated in the Phase 1 and Phase 2 clinical trials of CoronaVac. In the first phase, 29% of the volunteers reported adverse reactions within 14 days after vaccination, mainly pain and fatigue at the injection site.
Canadian Consulate General in Sao Paulo
United Nations Business Center – North Tower
Av. United Nations 12901 16th floor
Phone: (11) 5509 4321
Subscribe to our channel:
Plan your Trip
Do you want to speak to the newsroom or report any errors found on this page? Send a message to [email protected]